OneStream, Inc.(OS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

OS OneStream, Inc.

Halted 08-21 06:46:54 EDT

24.00

+0.00

0.00%

High24.00	Low24.00	Vol0.00
Open24.00	D1 Closing24.00	Amplitude0.00%
Mkt Cap4.56B	Tradable Cap2.03B	Total Shares190.00M
T/O65.27M	T/O Rate0.00%	Tradable Shares84.67M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"OS","market":"US","secType":"STK","nameCN":"OneStream, Inc.","latestPrice":24,"timestamp":1774987200000,"preClose":24,"halted":3,"volume":0,"delay":0,"changeRate":0,"floatShares":84669400,"shares":190000000,"eps":-0.28,"marketStatus":"Halted","change":0,"latestTime":"08-21 06:46:54 EDT","open":24,"high":24,"low":24,"amount":65272341.645588,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.28,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1787319000000},"marketStatusCode":1,"adr":0,"listingDate":1721793600000,"exchange":"NASDAQ","adjPreClose":24,"volumeRatio":0},"requestUrl":"/m/hq/s/OS/wiki","defaultTab":"wiki","newsList":[{"id":"2624638977","title":"OS Therapies bolsters funding to advance OST-HER2 program","url":"https://stock-news.laohu8.com/highlight/detail?id=2624638977","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624638977?lang=en_us&edition=fundamental","pubTime":"2026-04-03 06:40","pubTimestamp":1775169600,"startTime":"0","endTime":"0","summary":"An update from OS Therapies Incorporated ( ($OSTX) ) is now available. On March 31, 2026, OS Therapies entered into a securities purchase agreement...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/os-therapies-bolsters-funding-to-advance-ost-her2-program?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/os-therapies-bolsters-funding-to-advance-ost-her2-program?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4148","BK4097","OS","OSTX","OST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624505856","title":"Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of Response","url":"https://stock-news.laohu8.com/highlight/detail?id=2624505856","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624505856?lang=en_us&edition=fundamental","pubTime":"2026-04-02 19:00","pubTimestamp":1775127600,"startTime":"0","endTime":"0","summary":"Dose-Dependent Efficacy Results: As of the latest data cut, muzastotug achieved a 31% (8/26) confirmed overall response rate (ORR) in the combined 20 mg/kg dose cohorts, showing a clear improvement ov","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/02/3267222/0/en/Updated-Data-from-Phase-1b-2-Study-of-Muzastotug-in-Combination-with-KEYTRUDA-pembrolizumab-in-Late-line-Patients-with-Microsatellite-Stable-Colorectal-Cancer-Demonstrate-Improved-.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORR","MSS","CRC","LU0266512127.USD","BK4097","BK4139","BK4213","LU0456854461.SGD","ADAG","OS","PFS","BK4113","BK4211","BK4195"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624954487","title":"Press Release: Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2624954487","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624954487?lang=en_us&edition=fundamental","pubTime":"2026-04-02 05:00","pubTimestamp":1775077200,"startTime":"0","endTime":"0","summary":"In 2025, muzastotug showed 29% confirmed overall response rate  among 21 patients with MSS CRC in the 20 mg/kg dose cohorts. Median overall survival  for the 10 mg/kg cohorts was 19.4 months, with a median follow-up of 17.8 months. 4% overall discontinuation rate, no dose limiting toxicities, and no Grade 4 or 5 treatment-related adverse events  across 67 patients in all dose cohorts supports improved tolerability profile of muzastotug. Randomized Phase 2 trial enrollment ahead of plan, with potential updates in 2026 and results expected in 1H 2027; registration trial expected to begin once optimal dose regimen has been established. Cash and cash equivalents of $74.5 million as of December 31, 2025, plus proceeds raised from the ATM Offering in 2026 year-to-date, anticipated to provide cash runway into early 2028. SAN DIEGO, Calif. and SUZHOU, China, April 01, 2026  -- Adagene Inc.  , a platform-driven, clinical-stage biotechnology company transforming the discovery and development of ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HCC","BK4022","ORR","OS","BK4232","BK4139","BK4097","R","BK4006","ADAG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624545957","title":"OneStream Completes Go-Private Acquisition and Nasdaq Delisting","url":"https://stock-news.laohu8.com/highlight/detail?id=2624545957","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624545957?lang=en_us&edition=fundamental","pubTime":"2026-04-02 02:12","pubTimestamp":1775067176,"startTime":"0","endTime":"0","summary":"Onestream, Inc. Class A ( ($OS) ) just unveiled an update. On the closing date of its go-private transaction, OneStream, Inc. Class A entered into ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/onestream-completes-go-private-acquisition-and-nasdaq-delisting?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/onestream-completes-go-private-acquisition-and-nasdaq-delisting?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NQmain","BK4097","OS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624512176","title":"OneStream announces completion of acquisition by HG for $6.4B","url":"https://stock-news.laohu8.com/highlight/detail?id=2624512176","media":"TIPRANKS","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624512176?lang=en_us&edition=fundamental","pubTime":"2026-04-01 22:46","pubTimestamp":1775054775,"startTime":"0","endTime":"0","summary":"OneStream (OS) announced the completion of its acquisition by Hg. Minority investors include General Atlantic and Tidemark. The all-cash transactio...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/onestream-announces-completion-of-acquisition-by-hg-for-6-4b-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/onestream-announces-completion-of-acquisition-by-hg-for-6-4b-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4107","HG","OS","BK4097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624757514","title":"Onestream Announces Completion of Acquisition by Hg for $6.4 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2624757514","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624757514?lang=en_us&edition=fundamental","pubTime":"2026-04-01 22:38","pubTimestamp":1775054305,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nTUA1NZ2RR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OS","BK4097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624651477","title":"Press Release: OneStream Announces Completion of Acquisition by Hg for $6.4 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2624651477","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624651477?lang=en_us&edition=fundamental","pubTime":"2026-04-01 22:38","pubTimestamp":1775054280,"startTime":"0","endTime":"0","summary":"BIRMINGHAM, Mich., April 1, 2026 /PRNewswire/ -- OneStream, the leading enterprise Finance management platform that modernizes the Office of the CFO by unifying core Finance and operational functions -- including financial close, consolidation, reporting, planning and forecasting -- today announced the successful completion of its acquisition by Hg, a leading investor in European and transatlantic technology and services businesses. Minority investors include General Atlantic, a leading global investor, and Tidemark, a leading technology investment firm.The all-cash transaction values OneStream at approximately $6.4 billion in equity value. With the completion of the transaction, OneStream's Class A common stock has ceased trading on the NASDAQ.Backed by investors with deep expertise in scaling category-leading platforms for the Office of the CFO, OneStream is now privately held, with Tom Shea continuing to serve as CEO and the current OneStream leadership team remaining in place.As a ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AIPO","BK4097","AIYY","BK4023","AI","BK4528","BK4587","OS","BK4551","BK4585","BK4588","CHAT","BK4543","AGIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624514238","title":"OneStream completes acquisition by Hg in USD 6.4 billion deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2624514238","media":"Reuters","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624514238?lang=en_us&edition=fundamental","pubTime":"2026-04-01 22:34","pubTimestamp":1775054054,"startTime":"0","endTime":"0","summary":"Hg completed an all-cash acquisition of OneStream valuing equity at about USD 6.4 billion.OneStream shareholders will receive USD 24 per share in cash.Class A shares stopped trading on Nasdaq following deal close.OneStream will operate as a privately held company with Tom Shea remaining CEO.General Atlantic and Tidemark will hold minority stakes alongside Hg.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OneStream Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 01, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL2vB6ZC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OS","BK4097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624463590","title":"NASDAQ TRADE HALT CONTINUES  REASON NOT AVAILABLE AT 07:25 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2624463590","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624463590?lang=en_us&edition=fundamental","pubTime":"2026-04-01 19:25","pubTimestamp":1775042700,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT CONTINUES  REASON NOT AVAILABLE AT 07:25 AM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nAQN2LSQWO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4097","OS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624552529","title":"OS Therapies Files Prospectus Supplement for Share Resale","url":"https://stock-news.laohu8.com/highlight/detail?id=2624552529","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624552529?lang=en_us&edition=fundamental","pubTime":"2026-04-01 08:07","pubTimestamp":1775002053,"startTime":"0","endTime":"0","summary":"The latest update is out from OS Therapies Incorporated ( ($OSTX) ). On March 31, 2026, OS Therapies Incorporated filed a prospectus supplement wit...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/os-therapies-files-prospectus-supplement-for-share-resale?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/os-therapies-files-prospectus-supplement-for-share-resale?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OS","BK4097","OSTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623848355","title":"IMUNON Reports 2025 Financial Results and Provides Business Update Highlighting Significant Progress with Pivotal Phase 3 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2623848355","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623848355?lang=en_us&edition=fundamental","pubTime":"2026-03-31 20:00","pubTimestamp":1774958400,"startTime":"0","endTime":"0","summary":"IMNN-001 is the first frontline immunotherapy to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with advanced ovarian cancer Final Phase 2 clin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/31/3265395/0/en/IMUNON-Reports-2025-Financial-Results-and-Provides-Business-Update-Highlighting-Significant-Progress-with-Pivotal-Phase-3-Study.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRGS","BK4080","OS","BK4097","LU2065732104.USD","BK4231","SITC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623345052","title":"Press Release: Harbour BioMed Reports Full Year 2025 Financial Results: Sustained Global Collaboration Underpins Long-Term Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2623345052","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623345052?lang=en_us&edition=fundamental","pubTime":"2026-03-30 21:54","pubTimestamp":1774878840,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 30, 2026 /PRNewswire/ -- Harbour BioMed , a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced its financial results for the year ended December 31, 2025.Dr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed, commented: \"2025 marked a pivotal year for Harbour BioMed as we entered the third phase of our strategic evolution, with a clear roadmap toward our 2028 vision of becoming a global leading platform-based biopharmaceutical group.The Company's strategy is powered by three integrated growth engines. These include building a global leading AI-driven antibody discovery 'new infrastructure' through Nona Biosciences, expanding global partnerships through platform-based collaborations with multinational pharmaceutical companies, and unlocking the global value of its mid- to late-stage pipeline in immunology,","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","LU0266512127.USD","OS","MSS","BK4205","BK1161","02142","BK4113","R","CRC","NEN","BK4022","HCC","BK1583","BK4097","TSLP","BK4233","ORR","BK4213","LU0456854461.SGD","BK4590","BK1574","BK4006"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103719113","title":"Competition Intensifies in Second-Line EGFR 20ins NSCLC Treatment: Can Fumeitinib Challenge Sunvozertinib's Dominance?","url":"https://stock-news.laohu8.com/highlight/detail?id=1103719113","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103719113?lang=en_us&edition=fundamental","pubTime":"2026-03-27 16:00","pubTimestamp":1774598456,"startTime":"0","endTime":"0","summary":"The recommendation levels in the CSCO (Chinese Society of Clinical Oncology) guidelines serve as a bridge connecting high-level medical evidence with complex clinical decisions. These levels are not...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORR","OS","BK4097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622008723","title":"What's Behind The Jump In Corcept Therapeutics Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2622008723","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622008723?lang=en_us&edition=fundamental","pubTime":"2026-03-26 00:06","pubTimestamp":1774454760,"startTime":"0","endTime":"0","summary":"Shares of Corcept Therapeutics Incorporated (NASDAQ: CORT) are soaring Wednesday after the FDA approved a treatment for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/25/Crude-Oil-Price-Hike-Graph-Chart--Stock-.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/25/Crude-Oil-Price-Hike-Graph-Chart--Stock-.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/trading-ideas/movers/26/03/51461646/whats-behind-the-jump-in-corcept-therapeutics-stock","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/26/03/51461646/whats-behind-the-jump-in-corcept-therapeutics-stock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["CORT","BK4532","LU0566484027.USD","PFS","BK4195","OS","BK4007","BK4097","LU1559883803.SGD","BK4211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622107545","title":"Press Release: BeyondSpring Reports 2025 Year-End Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2622107545","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622107545?lang=en_us&edition=fundamental","pubTime":"2026-03-25 20:30","pubTimestamp":1774441800,"startTime":"0","endTime":"0","summary":"-- Phase 3 Survival Benefit Confirmed: Plinabulin combined with docetaxel. standard of care docetaxel in EGFR wild-type NSCLC patients whose tumors. progressed after first line therapy -- DUBLIN-3 study results published. discussions, BeyondSpring is advancing DUBLIN-4, a confirmatory global. Phase 3 study in a biomarker-selected EGFR wild-type NSCLC patient. sensitivity to checkpoint inhibitors -- a significant unmet need. Cell Press journal Med 2025 and presented at SITC 2025. \"2025 was a year of important clinical and operational progress for BeyondSpring and SEED Therapeutics,\" said Dr. Lan Huang, Co-Founder, Chairman and Chief Executive Officer of BeyondSpring. \"We advanced our Phase 3 Plinabulin program, generated meaningful clinical data, and strengthened our strategic and financial position.\". \"BeyondSpring made meaningful progress advancing Plinabulin in Phase 3 NSCLC, while SEED Therapeutics reached a critical milestone -- initiating its first clinical trial following IND cle","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","BYSI","BK4203","BK4195","BK4225","BK4139","BK4097","ORR","PFS","HR","OS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621809037","title":"Prestige Biopharma Announces Positive Topline Results from Comparative SAMSON-II Study for HD204, a Potential Biosimilar to Avastin (bevacizumab)","url":"https://stock-news.laohu8.com/highlight/detail?id=2621809037","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621809037?lang=en_us&edition=fundamental","pubTime":"2026-03-24 11:32","pubTimestamp":1774323120,"startTime":"0","endTime":"0","summary":"Primary endpoint of Overall Response Rate at Week 18 met, demonstrating clinical equivalence in patients with advanced non-squamous non-small cell lung cancer. SINGAPORE, March 24, 2026 /PRNewswire/ -- Prestige Biopharma today announced positivetopline results from its Phase 3 SAMSON-II study evaluating HD204, a proposed biosimilar to Avastin  in adult patients with advanced non-squamous non-small cell lung cancer .SAMSON-II is a randomized, double blind, parallel group, multicenter Phase 3 study conducted in 625 patients across 91 centers in 15 countries. Patients were randomized in a 1:1 ratio to receive HD204 or Avastin in combination with standard chemotherapy.\"These results illustrate the increasing precision with which biosimilarity can be established through advanced analytical and clinical PK studies,\" said Dr. Lisa Park, Chief Executive Officer of Prestige Biopharma. \"Our experience with HD204 supports the view that well-designed development programs can reliably anticipate cl","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/prestige-biopharma-announces-positive-topline-results-from-comparative-samson-ii-study-for-hd204-a-potential-biosimilar-to-avastin-bevacizumab-302722770.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","PBH","BK4195","BK4218","ORR","BK4007","PFS","ORR.AU","PK","BK7095","BK4097","BK4181","OS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621706487","title":"Amplia Therapeutics Reports Four Additional Complete Responses and Improved Overall Survival Data in Accent Pancreatic Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2621706487","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621706487?lang=en_us&edition=fundamental","pubTime":"2026-03-23 20:45","pubTimestamp":1774269900,"startTime":"0","endTime":"0","summary":"HIGHLIGHTS Formal centralized and independent analysis of the clinical response data from the ACCENT trial has been undertaken and updated analysis provided to the CompanyThe data confirm that five (5","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/23/3260403/0/en/Amplia-Therapeutics-Reports-Four-Additional-Complete-Responses-and-Improved-Overall-Survival-Data-in-Accent-Pancreatic-Cancer-Trial.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4195","INNMF","LENZ","ORR","BK4007","BK4097","OS","BK4161","PR","BK4139","CR","BK4213","PFS","BK4211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621033897","title":"Theriva™ Biologics Announces Positive End-of-Phase 2 Meeting with U.S. FDA Regarding the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2621033897","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621033897?lang=en_us&edition=fundamental","pubTime":"2026-03-23 20:00","pubTimestamp":1774267200,"startTime":"0","endTime":"0","summary":"– Successful meeting with FDA enables advancement into proposed Phase 3 clinical trial of VCN-01 in combination with gemcitabine/nab-paclitaxel for the first-line treatment of metastatic PDAC – – Comb","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/23/3260322/0/en/Theriva-Biologics-Announces-Positive-End-of-Phase-2-Meeting-with-U-S-FDA-Regarding-the-Design-of-a-Phase-3-Trial-of-VCN-01-in-Metastatic-Pancreatic-Ductal-Adenocarcinoma.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA","BK4087","LABU","BK4588","OS","BK4097","BK4585","PFS","CHMP","BK4081","BK4211","BK4195"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620779332","title":"Cellectis Reports Full Year 2025 Financial Results and Provides a Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2620779332","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620779332?lang=en_us&edition=fundamental","pubTime":"2026-03-20 07:21","pubTimestamp":1773962460,"startTime":"0","endTime":"0","summary":"Pivotal Phase 2 with lasme-cel in r/r B-ALL (BALLI-01 trial) ongoing Phase 1: 83% ORR at RP2D and 100% ORR in the target Phase 2 populationIn target Phase 2 population: 100% of patients became eligibl","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/19/3259513/0/en/Cellectis-Reports-Full-Year-2025-Financial-Results-and-Provides-a-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4187","IE0031619046.USD","LU0963586101.USD","LU2463526074.USD","BK4139","BK4006","IE00B66KJ199.SGD","IE00B19Z4B17.USD","ORR","BK4097","ASH","CRS","BK4109","CLLS","LU2065731478.USD","OS","IE00B7SZL793.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620267444","title":"OneStream Chief Revenue Officer Ken Hohenstein disposes of USD 1,399,000 in common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2620267444","media":"Reuters","labels":["insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620267444?lang=en_us&edition=fundamental","pubTime":"2026-03-19 04:45","pubTimestamp":1773866711,"startTime":"0","endTime":"0","summary":"Ken Hohenstein, Chief Revenue Officer of OneStream, reported option exercises and share sales in a Form 4 filing. On March 16, 2026, he acquired 49,204 shares through option exercises at prices of USD 10.65 and USD 14.51. On March 16, 2026, he sold 49,204 shares at USD 23.58. On March 17, 2026, he exercised options for 10,000 shares at USD 10.65 and sold 10,000 shares at USD 23.62. Following the reported transactions, he beneficially owned 985,571 shares directly.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OneStream Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL5PqZSG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"OneStream Chief Revenue Officer Ken Hohenstein disposes of USD 1,399,000 in common shares","news_tag":"insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OS","BK4097"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.onestream.com;investor.onestream.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0.0217},{"period":"1year","weight":0.2091},{"period":"ytd","weight":0.3058}],"compareEarnings":[{"period":"1week","weight":-0.0196},{"period":"1month","weight":0.0191},{"period":"3month","weight":0.0227},{"period":"6month","weight":0.1061},{"period":"1year","weight":0.1951},{"period":"ytd","weight":0.1183}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"exchange":"NASDAQ","name":"OneStream, Inc.","nameEN":"OneStream, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"OneStream, Inc.(OS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest OneStream, Inc.(OS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"OneStream, Inc.,OS,OneStream, Inc.股票,OneStream, Inc.股票老虎,OneStream, Inc.股票老虎国际,OneStream, Inc.行情,OneStream, Inc.股票行情,OneStream, Inc.股价,OneStream, Inc.股市,OneStream, Inc.股票价格,OneStream, Inc.股票交易,OneStream, Inc.股票购买,OneStream, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"OneStream, Inc.(OS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest OneStream, Inc.(OS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}